Literature DB >> 25248857

Network medicine analysis of COPD multimorbidities.

Solène Grosdidier, Antoni Ferrer, Rosa Faner, Janet Piñero, Josep Roca, Borja Cosío, Alvar Agustí, Joaquim Gea, Ferran Sanz, Laura I Furlong.   

Abstract

BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) often suffer concomitant disorders that worsen significantly their health status and vital prognosis. The pathogenic mechanisms underlying COPD multimorbidities are not completely understood, thus the exploration of potential molecular and biological linkages between COPD and their associated diseases is of great interest.
METHODS: We developed a novel, unbiased, integrative network medicine approach for the analysis of the diseasome, interactome, the biological pathways and tobacco smoke exposome, which has been applied to the study of 16 prevalent COPD multimorbidities identified by clinical experts.
RESULTS: Our analyses indicate that all COPD multimorbidities studied here are related at the molecular and biological level, sharing genes, proteins and biological pathways. By inspecting the connections of COPD with their associated diseases in more detail, we identified known biological pathways involved in COPD, such as inflammation, endothelial dysfunction or apoptosis, serving as a proof of concept of the methodology. More interestingly, we found previously overlooked biological pathways that might contribute to explain COPD multimorbidities, such as hemostasis in COPD multimorbidities other than cardiovascular disorders, and cell cycle pathway in the association of COPD with depression. Moreover, we also observed similarities between COPD multimorbidities at the pathway level, suggesting common biological mechanisms for different COPD multimorbidities. Finally, chemicals contained in the tobacco smoke target an average of 69% of the identified proteins participating in COPD multimorbidities.
CONCLUSIONS: The network medicine approach presented here allowed the identification of plausible molecular links between COPD and comorbid diseases, and showed that many of them are targets of the tobacco exposome, proposing new areas of research for understanding the molecular underpinning of COPD multimorbidities.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25248857      PMCID: PMC4177421          DOI: 10.1186/s12931-014-0111-4

Source DB:  PubMed          Journal:  Respir Res        ISSN: 1465-9921


  37 in total

Review 1.  Evaluation of the potential effects of ingredients added to cigarettes. Part 2: chemical composition of mainstream smoke.

Authors:  K Rustemeier; R Stabbert; H J Haussmann; E Roemer; E L Carmines
Journal:  Food Chem Toxicol       Date:  2002-01       Impact factor: 6.023

2.  β2-adrenergic receptor polymorphisms, asthma and COPD: two large population-based studies.

Authors:  M Thomsen; B G Nordestgaard; A A Sethi; A Tybjærg-Hansen; M Dahl
Journal:  Eur Respir J       Date:  2011-11-10       Impact factor: 16.671

3.  The Unified Medical Language System (UMLS): integrating biomedical terminology.

Authors:  Olivier Bodenreider
Journal:  Nucleic Acids Res       Date:  2004-01-01       Impact factor: 16.971

4.  Familial aggregation of FEF(25-75) and FEF(25-75)/FVC in families with severe, early onset COPD.

Authors:  D L DeMeo; V J Carey; H A Chapman; J J Reilly; L C Ginns; F E Speizer; S T Weiss; E K Silverman
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

5.  β2 -adrenergic receptor Thr164IIe polymorphism, blood pressure and ischaemic heart disease in 66 750 individuals.

Authors:  M Thomsen; M Dahl; A Tybjaerg-Hansen; B G Nordestgaard
Journal:  J Intern Med       Date:  2011-09-29       Impact factor: 8.989

Review 6.  Human diseases through the lens of network biology.

Authors:  Laura I Furlong
Journal:  Trends Genet       Date:  2012-12-07       Impact factor: 11.639

7.  Chronic obstructive pulmonary disease: effects beyond the lungs.

Authors:  Peter J Barnes
Journal:  PLoS Med       Date:  2010-03-16       Impact factor: 11.069

8.  Concentration-dependent effects of adrenaline on the profile of insulin secretion from isolated human islets of Langerhans.

Authors:  R J Lacey; H C Cable; R F James; N J London; J H Scarpello; N G Morgan
Journal:  J Endocrinol       Date:  1993-09       Impact factor: 4.286

9.  Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease.

Authors:  Miguel Divo; Claudia Cote; Juan P de Torres; Ciro Casanova; Jose M Marin; Victor Pinto-Plata; Javier Zulueta; Carlos Cabrera; Jorge Zagaceta; Gary Hunninghake; Bartolome Celli
Journal:  Am J Respir Crit Care Med       Date:  2012-05-03       Impact factor: 21.405

10.  COPD and the solar system: introducing the chronic obstructive pulmonary disease comorbidome.

Authors:  Leonardo M Fabbri; Bianca Beghé; Alvar Agustí
Journal:  Am J Respir Crit Care Med       Date:  2012-07-15       Impact factor: 21.405

View more
  16 in total

1.  Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014.

Authors:  Alvar Agustí; Josep Maria Antó; Charles Auffray; Ferran Barbé; Esther Barreiro; Jordi Dorca; Joan Escarrabill; Rosa Faner; Laura I Furlong; Judith Garcia-Aymerich; Joaquim Gea; Bertil Lindmark; Eduard Monsó; Vicente Plaza; Milo A Puhan; Josep Roca; Juan Ruiz-Manzano; Laura Sampietro-Colom; Ferran Sanz; Luis Serrano; James Sharpe; Oriol Sibila; Edwin K Silverman; Peter J Sterk; Jacob I Sznajder
Journal:  Am J Respir Crit Care Med       Date:  2015-02-15       Impact factor: 21.405

Review 2.  Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management.

Authors:  Prescott G Woodruff; Alvar Agusti; Nicolas Roche; Dave Singh; Fernando J Martinez
Journal:  Lancet       Date:  2015-05-02       Impact factor: 79.321

Review 3.  Network medicine in Cardiovascular Research.

Authors:  Laurel Y Lee; Arvind K Pandey; Bradley A Maron; Joseph Loscalzo
Journal:  Cardiovasc Res       Date:  2021-08-29       Impact factor: 10.787

4.  DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes.

Authors:  Janet Piñero; Núria Queralt-Rosinach; Àlex Bravo; Jordi Deu-Pons; Anna Bauer-Mehren; Martin Baron; Ferran Sanz; Laura I Furlong
Journal:  Database (Oxford)       Date:  2015-04-15       Impact factor: 3.451

Review 5.  From big data analysis to personalized medicine for all: challenges and opportunities.

Authors:  Akram Alyass; Michelle Turcotte; David Meyre
Journal:  BMC Med Genomics       Date:  2015-06-27       Impact factor: 3.063

Review 6.  Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review.

Authors:  Manuel B Huber; Margarethe E Wacker; Claus F Vogelmeier; Reiner Leidl
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

7.  Hospital admissions and mortality in patients with COPD exacerbations and vertebral body compression fractures.

Authors:  Sergi Pascual-Guardia; Diana Badenes-Bonet; Clara Martin-Ontiyuelo; Flavio Zuccarino; Judith Marín-Corral; Alejandro Rodríguez; Esther Barreiro; Joaquim Gea
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-06-21

8.  Impact of Comorbidities Among Medicaid Enrollees With Chronic Obstructive Pulmonary Disease, United States, 2009.

Authors:  Gloria Westney; Marilyn G Foreman; Junjun Xu; Marshaleen Henriques King; Eric Flenaugh; George Rust
Journal:  Prev Chronic Dis       Date:  2017-04-13       Impact factor: 2.830

9.  DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants.

Authors:  Janet Piñero; Àlex Bravo; Núria Queralt-Rosinach; Alba Gutiérrez-Sacristán; Jordi Deu-Pons; Emilio Centeno; Javier García-García; Ferran Sanz; Laura I Furlong
Journal:  Nucleic Acids Res       Date:  2016-10-19       Impact factor: 16.971

10.  A needs assessment to determine the need for respiratory therapy in complex continuing care: A methods paper.

Authors:  Jason W Nickerson
Journal:  Can J Respir Ther       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.